Literature DB >> 20471318

Antiretroviral drugs.

Erik De Clercq1.   

Abstract

In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'-dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors (FIs), co-receptor inhibitors (CRIs) and integrase inhibitors (INIs). The INIs (i.e. raltegravir) represent the most recent advance in the search for effective and selective anti-HIV agents. Combination of several anti-HIV drugs [often referred to as highly active antiretroviral therapy (HAART)] has drastically altered AIDS from an almost uniformly fatal disease to a chronic manageable one.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471318     DOI: 10.1016/j.coph.2010.04.011

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  50 in total

1.  Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

Review 2.  Microbicides: topical prevention against HIV.

Authors:  Robin J Shattock; Zeda Rosenberg
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

3.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

4.  Structural investigation of protonated azidothymidine and protonated dimer.

Authors:  Blake E Ziegler; Rick A Marta; Michael B Burt; Sabrina M Martens; Jonathan K Martens; Terry B McMahon
Journal:  J Am Soc Mass Spectrom       Date:  2013-12-04       Impact factor: 3.109

5.  The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells.

Authors:  Ansgar Brüning; Petra Burger; Andrea Gingelmaier; Ioannis Mylonas
Journal:  Invest New Drugs       Date:  2011-06-29       Impact factor: 3.850

6.  Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Authors:  D Rajotte; S Tremblay; A Pelletier; P Salois; L Bourgon; R Coulombe; S Mason; L Lamorte; C F Sturino; R Bethell
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

7.  Structure of a dihydroxycoumarin active-site inhibitor in complex with the RNase H domain of HIV-1 reverse transcriptase and structure-activity analysis of inhibitor analogs.

Authors:  Daniel M Himmel; Nataliya S Myshakina; Tatiana Ilina; Alexander Van Ry; William C Ho; Michael A Parniak; Eddy Arnold
Journal:  J Mol Biol       Date:  2014-05-17       Impact factor: 5.469

8.  Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.

Authors:  F Matthew Kuhlmann; John I Robinson; Gregory R Bluemling; Catherine Ronet; Nicolas Fasel; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

9.  Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.

Authors:  Thomas W North; Andradi Villalobos; Selwyn J Hurwitz; Jesse D Deere; Joanne Higgins; Payel Chatterjee; Sijia Tao; Robert C Kauffman; Paul A Luciw; James J Kohler; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

10.  Phospholipids showing complex bilayer phase transitions. II. Four sulfur-containing phosphatidylcholines.

Authors:  J Hajdu; J M Sturtevant
Journal:  Chem Phys Lipids       Date:  1990-09       Impact factor: 3.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.